All publications
Self-emulsifying drug delivery systems (SEDDS): In vivo-proof of concept for oral delivery of insulin glargine
International Journal of Pharmaceutics 639 - 122964 - May 2023
In this study, lipophilicity of insulin glargine (IG) was successfully increased via hydrophobic ion pairing (HIP) with sodium octadecyl sulfate to enable incorporation into self-emulsifying drug delivery systems (SEDDS). The SEDDS formulations F1 and F2 were administered to rats via oral gavage and resulted in a bioavailability of 0.55% and 0.44%, corresponding to a 7.7-fold and 6.2-fold increased bioavailability, respectively. Thus, incorporation of complexed insulin glargine into SEDDS formulations provides a promising approach to facilitate its oral absorption.
An All-Purpose Vehicle for Low-Energy Capsule Filling
Tablets&Capsules - Apr 2023
Capsules are perceived as elegant, easy-to-swallow dosage forms, widely used for delivery of nutraceutical and medicinal preparations. Advances in capsule technologies have hugely facilitated the incorporation of liquid, semi-solid, and solid ingredients into capsules.
LIPID-BASED EXCIPIENTS – Misconceptions About Lipid-Based Drug Delivery
Drug Development & Delivery - Apr 2023
Oxidative Stability in Lipid Formulations: a Review of the Mechanisms, Drivers, and Inhibitors of Oxidation
AAPS PharmSciTech – Vol. 23 – Article number 151 - May 2022
Cannabinoid molecules and their love of lipid excipients
Pharmaceuticals & Cosmetic Review - Feb 2022
Carving out a Niche in Pharmaceutical Drug Delivery
Pharma Times – Vol. 53 – No. 12 - Dec 2021
GELUCIRE® 4414 for type IV lipid based formulations and their in vitro in vivo performance evaluation
AAPS PharmSci360 – Philadelphia (USA) - 2021
In this study, Gelucire® 44/14 in type IV lipid-based formulation has been evaluated to increase the solubility and in vivo performance of ticagrelor.
Lipid excipients to unlock oral bioavailability issues
American Pharmaceutical Review - Feb 2021
Table of content:
Introduction
Chapter I : Lipids, reliable partners to enhance oral bioavailability of poorly water-soluble drugs
Chapter II : Lipids to enhance the intestinal permeability of poorly permeable drugs
Chapter III : Targeting lymphatic absorption with appropriate lipid excipients selection
Chapter IV : Mitigating food effect with lipid-based formulations
Chapter V : Gattefossé range of functional excipients
for oral bioavailability enhancement
DOs and DON’Ts for developing successful SEDDS formulations to enhance API bioavailability
Tablets&Capsules, p.37-39 - Apr 2020